BioCentury
ARTICLE | Emerging Company Profile

Optimized antibiotics

Why Entasis is developing broad-spectrum antibiotics for narrow indications

April 18, 2016 7:00 AM UTC

Entasis Therapeutics Inc.'s broad-spectrum antibiotic candidates are dose-optimized for specific pathogens and could tackle multidrug-resistant Gram-negative infections while limiting the spread of resistance.

Entasis spun out of AstraZeneca plc last year with lead compound ETX0914, a first-in-class oral benzisoxazole DNA gyrase and topoisomerase IV inhibitor in Phase II testing to treat uncomplicated gonorrhea. AZ is eligible for undisclosed royalties. ...